Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Williams, SK; Maier, O; Fischer, R; Fairless, R; Hochmeister, S; Stojic, A; Pick, L; Haar, D; Musiol, S; Storch, MK; Pfizenmaier, K; Diem, R.
Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
PLoS One. 2014; 9(2):e90117-e90117 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Hochmeister Sonja
Storch Maria
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 6
| | | | | |
Abstract:
Tumour necrosis factor (TNF) is a proinflammatory cytokine that is known to regulate inflammation in a number of autoimmune diseases, including multiple sclerosis (MS). Although targeting of TNF in models of MS has been successful, the pathological role of TNF in MS remains unclear due to clinical trials where the non-selective inhibition of TNF resulted in exacerbated disease. Subsequent experiments have indicated that this may have resulted from the divergent effects of the two TNF receptors, TNFR1 and TNFR2. Here we show that the selective targeting of TNFR1 with an antagonistic antibody ameliorates symptoms of the most common animal model of MS, experimental autoimmune encephalomyelitis (EAE), when given following both a prophylactic and therapeutic treatment regime. Our results demonstrate that antagonistic TNFR1-specific antibodies may represent a therapeutic approach for the treatment of MS in the future.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Antibodies - pharmacology
Disease Models, Animal -
Encephalomyelitis, Autoimmune, Experimental - genetics
Encephalomyelitis, Autoimmune, Experimental - immunology
Encephalomyelitis, Autoimmune, Experimental - pathology
Encephalomyelitis, Autoimmune, Experimental - therapy
Female -
Gene Expression -
Immunotherapy -
Mice -
Mice, Inbred C57BL -
Mice, Knockout -
Molecular Targeted Therapy -
Multiple Sclerosis - genetics
Multiple Sclerosis - immunology
Multiple Sclerosis - pathology
Multiple Sclerosis - therapy
Receptors, Tumor Necrosis Factor, Type I - antagonists & inhibitors
Receptors, Tumor Necrosis Factor, Type I - deficiency
Receptors, Tumor Necrosis Factor, Type I - genetics
Receptors, Tumor Necrosis Factor, Type II - antagonists & inhibitors
Receptors, Tumor Necrosis Factor, Type II - deficiency
Receptors, Tumor Necrosis Factor, Type II - genetics

© Meduni Graz Impressum